| scholarly article | Q13442814 |
| P356 | DOI | 10.1259/BJR.20170196 |
| P8608 | Fatcat ID | release_smx64u5oxjglvhe3lrp55zo7t4 |
| P932 | PMC publication ID | 5594997 |
| P698 | PubMed publication ID | 28590814 |
| P50 | author | Raphael Jumeau | Q88372045 |
| P2093 | author name string | David Roberge | |
| Édith Filion | |||
| Louise Lambert | |||
| Houda Bahig | |||
| Toni Vu | |||
| Marie-Pierre Campeau | |||
| Robert Doucet | |||
| P2860 | cites work | A systematic review of outcomes following stereotactic ablative radiotherapy in the treatment of early-stage primary lung cancer | Q38790915 |
| Incidence and risk factors for chest wall toxicity after risk-adapted stereotactic radiotherapy for early-stage lung cancer | Q43515284 | ||
| Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer | Q44377522 | ||
| Clinical prognostic factors and grading system for rib fracture following stereotactic body radiation therapy (SBRT) in patients with peripheral lung tumors | Q45711107 | ||
| Chest wall toxicity after stereotactic body radiotherapy for malignant lesions of the lung and liver | Q45845458 | ||
| Predicting chest wall pain from lung stereotactic body radiotherapy for different fractionation schemes. | Q45987368 | ||
| Predictive parameters of CyberKnife fiducial-less (XSight Lung) applicability for treatment of early non-small cell lung cancer: a single-center experience | Q48713875 | ||
| Application of robotic stereotactic radiotherapy to peripheral stage I non-small cell lung cancer with curative intent | Q48841157 | ||
| Comparison of Ray Tracing and Monte Carlo Calculation Algorithms for Thoracic Spine Lesions Treated With CyberKnife-Based Stereotactic Body Radiation Therapy. | Q50968030 | ||
| The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy. | Q52430649 | ||
| High-risk CT features for detection of local recurrence after stereotactic ablative radiotherapy for lung cancer. | Q53098154 | ||
| Bioeffect modeling and equieffective dose concepts in radiation oncology--terminology, quantities and units. | Q53120652 | ||
| Radiation-induced rib fractures after hypofractionated stereotactic body radiation therapy of non-small cell lung cancer: a dose- and volume-response analysis. | Q53356440 | ||
| SABR in NSCLC--the beginning of the end or the end of the beginning? | Q53621797 | ||
| SPACE - A randomized study of SBRT vs conventional fractionated radiotherapy in medically inoperable stage I NSCLC. | Q53781022 | ||
| Outcomes of Risk-Adapted Fractionated Stereotactic Radiotherapy for Stage I Non–Small-Cell Lung Cancer | Q59587541 | ||
| Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study | Q80587769 | ||
| Prediction of chest wall toxicity from lung stereotactic body radiotherapy (SBRT) | Q83386090 | ||
| Dosimetric predictors of chest wall pain after lung stereotactic body radiotherapy | Q83561888 | ||
| Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy | Q83768631 | ||
| Evaluation of Patients With Pulmonary Nodules: When Is It Lung Cancer? | Q22306068 | ||
| Dose-volume parameters predict for the development of chest wall pain after stereotactic body radiation for lung cancer | Q30421587 | ||
| Chest wall volume receiving >30 Gy predicts risk of severe pain and/or rib fracture after lung stereotactic body radiotherapy | Q30448358 | ||
| Stereotactic body radiation therapy: the report of AAPM Task Group 101. | Q30451917 | ||
| Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials | Q30656342 | ||
| Stereotactic radiotherapy with real-time tumor tracking for non-small cell lung cancer: clinical outcome | Q33419548 | ||
| Evaluating proton stereotactic body radiotherapy to reduce chest wall dose in the treatment of lung cancer | Q33860897 | ||
| Obesity increases the risk of chest wall pain from thoracic stereotactic body radiation therapy | Q33887571 | ||
| Stereotactic body radiation therapy for inoperable early stage lung cancer | Q34010065 | ||
| Non–Small Cell Lung Cancer | Q34129295 | ||
| Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer | Q34575077 | ||
| Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch(®) patient registry | Q35646076 | ||
| Low incidence of chest wall pain with a risk-adapted lung stereotactic body radiation therapy approach using three or five fractions based on chest wall dosimetry | Q37698823 | ||
| Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis | Q38021143 | ||
| Management of early-stage non-small cell lung cancer using stereotactic ablative radiotherapy: controversies, insights, and changing horizons | Q38286602 | ||
| P433 | issue | 1075 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 20170196 | |
| P577 | publication date | 2017-06-07 | |
| P1433 | published in | British Journal of Radiology | Q15758529 |
| P1476 | title | A dosimetric parameter to limit chest wall toxicity in SABR of NSCLC. | |
| P478 | volume | 90 |
Search more.